

Lista de lucrări

Candidat: Mocan Tudor-loan

a) Lista celor 10 lucrări considerate cele mai relevante

1. **Mocan T**, Ilies M, Nenu I, Craciun R, Horhat A, Susa R, Minciuna I, Rusu I, Mocan LP, Seicean A, Iuga CA, Hajjar NA, Sparchez M, Leucuta DC, Sparchez Z. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94:1-8. doi: 10.1016/j.intimp.2021.107467, ISSN: 1878-1705, FI 5.71, Q1.
2. **Mocan T**, Stiufiuc R, Popa C, Nenu I, Pestean C, Nagy AL, Mocan LP, Leucuta DC, Hajjar NA, Sparchez Z. Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. Sci Rep. 2021; 11: 1-9. doi: 10.1038/s41598-020-79917-4, ISSN 2045-2322, FI 4.99, Q1.
3. **Mocan T**, Kang DW, Molloy BJ, Jeon H, Spârchez ZA, Beyoğlu D, Idle JR. Plasma fetal bile acids 7 α -hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis. Sci Rep. 2021; 11:1-9. doi: 10.1038/s41598-021-87921-5, ISSN 2045-2322, FI 4.99, Q1.
4. **Mocan T**, Nenu I, Crăciun R, Spârchez Z. Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare? J Gastroenterol Hepatol. 2021;36:1518-1528. doi: 10.1111/jgh.15376, ISSN: 0815-9319, FI 4.36, Q2.
5. **Mocan T**, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and

therapeutic perspectives. Clin Transl Oncol. 2019; 21:702-712. doi: 10.1007/s12094-018-1975-4, ISSN:1699-3055, FI 2.73, Q2.

6. Mocan LP, Craciun R, Grapa C, Melincovici CS, Rusu I, Al Hajjar N, Sparchez Z, Leucuta D, Ilies M, Sparchez M, **Mocan T**, Mihiu CM. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. Cancer Immunol Immunother. 2023;72:1003-1014, doi: 10.1007/s00262-022-03309-y, ISSN 1432-0851, IF 5.1, Q1, autor corespondent.

7. Salzmann RJS, **Mocan T**, Willms AG, Klein A, Schwab R, Mois E, Grapa C, Mocan LP, Craciun R, Sparchez Z, Schmidt-Wolf IGH, Best J, Schmidt HH, Krawczyk M, Robson SC, Lukacs-Kornek V, Kornek MT. AI-guided additive scoring model for differential diagnosis of primary liver cancer. JHEP Rep. 2026;8:101826, doi: 10.1016/j.jhepr.2026.101826, ISSN 2589-5559, IF 7.5, Q1, statut de prim autor.

8. Urban SK, **Mocan T**, Sängler H, Lukacs-Kornek V, Kornek M. Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application. Semin Liver Dis. 2019; 39:70-77. doi: 10.1055/s-0038-1676122, ISSN 1098-8971, IF 4.45, Q1, statut de prim autor.

9. Słomka A, Wang B, **Mocan T**, Horhat A, Willms AG, Schmidt-Wolf IGH, Strassburg CP, Gonzalez-Carmona MA, Lukacs-Kornek V, Kornek MT. Extracellular Vesicles and Circulating Tumour Cells - complementary liquid biopsies or standalone concepts? Theranostics. 2022; 12:5836-5855. doi: 10.7150/thno.73400, ISSN · 1838-7640, IF 11.55, Q1.

10. Banales JM, Rodrigues PM, Affò S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Klumpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C; **International CCA Consensus Consortium**. Cholangiocarcinoma 2026: status

quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026;23:65-96, doi: 10.1038/s41575-025-01153-w, ISSN 1759-5053, IF 51, Q1.

b) Teză de doctorat

Titlu: „**Diagnostic, prognostic si tratament in carcinomul hepatocelular**”

Anul susținerii: 2022

Conducător științific: Prof. dr. Zeno Adrian Sparchez

Instituția eliberatoare a diplomei de doctor: Universitatea de Medicină și Farmacie „Iuliu Hațieganu” din Cluj-Napoca

Calificativ: Excelent/Summa cum laude

c) Cărți și capitole în cărți

1. Crăciun R, **Mocan T**, Spârchez Z. Ultrasound-Based Methods for the Assessment of Advanced Liver Disease and Portal Hypertension [Internet]. Ultrasound - The Next Step in Clinical Evaluation. IntechOpen; 2025. <https://doi.org/10.5772/intechopen.1010916>
2. Sparchez Z, **Mocan T**, Radu P. Old versus New – Tumor Ablation versus Tumor Nanoablation with Particular Emphasis on Liver Tumors [Internet]. Recent Advances in Liver Diseases and Surgery. InTech; 2015. <https://doi.org/10.5772/61008>

d) Articole/studii in extenso, publicate în reviste din fluxul științific internațional principal

i. Articole în reviste cotate ISI

1. **Mocan T.**, Spârchez, Z., Crăciun, R., Bora, C. N., & Leucuța, D. C. (2019). Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. *Clinical and Translational Oncology*, 21(6), 702–712. ISSN: 1699-3055. FI: 2.858, Q3. PMID: 30387047.
2. Spârchez Z., **Mocan T.**, Hagi, C., Kacso, G., Zaharie, T., Rusu, I., Al Hajjar, N., Leucuța, D. C., & Spârchez, M. (2019). Real-Time Contrast-Enhanced-Guided Biopsy Compared with Conventional Ultrasound-Guided Biopsy in the Diagnosis of Hepatic Tumors on a Background of Advanced Chronic Liver Disease. *Ultrasound in Medicine and Biology*, 45(11), 2915–2924. ISSN: 0301-5629. FI: 2.514, Q2. PMID: 31447237.
3. Urba S. K., **Mocan T.**, Sănger, H., Lukacs-Kornek, V., & Kornek, M. (2019). Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application. *Seminars in Liver Disease*, 39(1), 70–77. ISSN: 0272-8087. FI: 5.509, Q1. PMID: 30654391.
4. Spârchez Z., **Mocan T.**, Radu, P., Anton, O., & Bolog, N. (2016). Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma. *Medical Ultrasonography*, 18(1), 96–102. ISSN: 2066-8643. FI: 1.328, Q3. PMID: 26962561.
5. Spârchez, Z., **Mocan T.** (2017). Hepatocellular Carcinoma Occurrence and Recurrence after Antiviral Treatment in HCV-Related Cirrhosis. *Journal of Gastrointestinal and Liver Diseases*, 26(4), 403–410. ISSN: 1841-8724. FI: 1.884, Q3. PMID: 29253056.
6. Spârchez, Z., **Mocan T.** (2018). Contemporary role of liver biopsy in hepatocellular carcinoma. *World Journal of Hepatology*, 10(7), 452–461. ISSN: 1948-5182. FI: 2.157, Q3. PMID: 30079131.
7. Spârchez, Z., **Mocan T.**, Radu, P., Mocan, L. P., Spârchez, M., Leucuța, D. C., & Al Hajjar, N. (2018). Prognostic Factors after Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma. *Journal of Gastrointestinal and Liver Diseases*, 27(4), 399–407. ISSN: 1841-8724. FI: 1.880, Q3. PMID: 30574622.
8. Spârchez, Z., **Mocan T.**, Al Hajjar, N., Bartoș, A., Hagi, C., Matei, D., Crăciun, R., Mocan, L. P., Spârchez, M., & Leucuța, D. C. (2019). Percutaneous ultrasound guided

- radiofrequency and microwave ablation in the treatment of hepatic metastases. *Medical Ultrasonography*, 21(3), 217–224. ISSN: 2066-8643. FI: 1.726, Q3. PMID: 31476199.
9. **Mocan T.**, Simão, A. L., Castro, R. E., Rodrigues, C. M. P., Słomka, A., Wang, B., Strassburg, C., Wöhler, A., Willms, A. G., & Kornek, M. (2020). Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? *Journal of Clinical Medicine*, 9(5), 1541. ISSN: 2077-0383. FI: 4.241, Q1. PMID: 32443747.
 10. Spârchez, Z., **Mocan T.**, Radu, P., Nenu, I., Comşa, M., Al Hajjar, N., Moiş, E., Bartoş, A., Kacso, G., & Spârchez, M. (2020). Microwave ablation in the treatment of liver tumors. *Medical Ultrasonography*, 22(4), 451–460. ISSN: 2066-8643. FI: 1.726, Q3. PMID: 32905567.
 11. Spârchez, Z., **Mocan T.**, Matei, D., Popa, O., & Al Hajjar, N. (2021). Bleeding after Microwave Ablation in Hepatocellular Carcinoma: Successful Treatment with Percutaneous Ultrasound-Guided Cyanoacrylate Glue Embolization. *Ultraschall in der Medizin*, 42(2), 202–203. ISSN: 0172-4614. FI: 4.279, Q1. PMID: 32131084.
 12. **Mocan T.**, Stiufiuc, R., Popa, C., Nenu, I., Pestean, C., Nagy, A. L., Mocan, L. P., Leucuța, D. C., Al Hajjar, N., & Spârchez, Z. (2021). Percutaneous ultrasound guided PEG-coated gold nanoparticles enhanced radiofrequency ablation in liver. *Scientific Reports*, 11(1), 1316. ISSN: 2045-2322. FI: 4.996, Q1. PMID: 33446793.
 13. **Mocan T.**, Kang, D. W., Molloy, B. J., Jeon, H., Spârchez, Z. A., Beyoğlu, D., & Idle, J. R. (2021). Plasma fetal bile acids 7 α -hydroxy-3-oxochol-4-en-24-oic acid and 3-oxachola-4,6-dien-24-oic acid indicate severity of liver cirrhosis. *Scientific Reports*, 11(1), 8298. ISSN: 2045-2322. FI: 4.996, Q1. PMID: 33859329.
 14. Spârchez, Z., Crăciun, R., Caraiani, C., Horhat, A., Nenu, I., Procopeţ, B., Spârchez, M., Ștefănescu, H., & **Mocan T.** (2021). Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma. *Journal of Clinical Medicine*, 10(5), 903. ISSN: 2077-0383. FI: 4.241, Q1. PMID: 33668839.

15. **Mocan T.**, Nenu, I., Crăciun, R., & Spârchez, Z. (2021). Treatment of hepatitis C virus infection in patients with hepatocellular carcinoma: Truth or dare? *Journal of Gastroenterology and Hepatology*, 36(6), 1518–1528. ISSN: 0815-9319. FI: 4.012, Q2. PMID: 33326142.
16. **Mocan T.**, Horhat, A., Moiş, E., Graur, F., Tefas, C., Crăciun, R., Nenu, I., Spârchez, M., & Spârchez, Z. (2021). Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how? *World Journal of Gastrointestinal Oncology*, 13(12), 2050–2063. ISSN: 1948-5204. FI: 3.368, Q2. PMID: 35070041.
17. **Mocan T.**, Ilieş, M., Nenu, I., Crăciun, R., Horhat, A., Susa, R., Minciună, I., Rusu, I., Mocan, L. P., Seicean, A., Iuga, C. A., Al Hajjar, N., Spârchez, M., Leucuța, D. C., & Spârchez, Z. (2021). Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. *International Immunopharmacology*, 94, 107467. ISSN: 1567-5769. FI: 4.932, Q2. PMID: 33611059.
18. Mocan, L. P., Ilieş, M., Melincovici, C. S., Spârchez, M., Crăciun, R., Nenu, I., Horhat, A., Tefas, C., Spârchez, Z., Iuga, C. A., **Mocan T.**, & Mişu, C. M. (2022). Novel approaches in search for biomarkers of cholangiocarcinoma. *World Journal of Gastroenterology*, 28(15), 1508–1525. ISSN: 1007-9327. FI: 5.374, Q1. PMID: 35582128.
19. Spârchez, M., **Mocan T.**, Caraianni, C., Rusu, I., & Spârchez, Z. A. (2022). The added value of CEUS and ultrasound-guided biopsy in diagnosing an aggressive desmoplastic small round cell tumour of peritoneum. *Medical Ultrasonography*, 24(4), 499–502. ISSN: 2066-8643. FI: 2.034, Q3. PMID: 35437528.
20. Mocan, L. P., Crăciun, R., Grapă, C., Melincovici, C. S., Rusu, I., Al Hajjar, N., Spârchez, Z., Leucuța, D., Ilieş, M., Spârchez, M., **Mocan T.**, & Mişu, C. M. (2023). PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma. *Cancer Immunology, Immunotherapy*, 72(4), 1003–1014. ISSN: 0340-7004. FI: 6.422, Q1. PMID: 36251029.

21. Spârchez, Z., Crăciun, R., Nenu, I., Mocan, L. P., Spârchez, M., & **Mocan T.** (2023). Refining Liver Biopsy in Hepatocellular Carcinoma. *Biomedicines*, 11(8), 2324. ISSN: 2227-9059. FI: 4.757, Q1. PMID: 37626820.
22. Piekuś-Słomka, N., Mocan, L. P., Shkreli, R., Grapă, C., Denkiewicz, K., Wesołowska, O., Kornek, M., Spârchez, Z., Słomka, A., Crăciun, R., & **Mocan T.** (2023). Don't Judge a Book by Its Cover: The Role of Statins in Liver Cancer. *Cancers*, 15(20), 5100. ISSN: 2072-6694. FI: 6.575, Q1. PMID: 37894467.
23. Mocan, L. P., Grapă, C., Crăciun, R., Pralea, I. E., Uifălean, A., Soporan, A. M., Mureșan, X. M., Iacobescu, M., Al Hajjar, N., Mișu, C. M., Spârchez, Z., **Mocan T.**, & Iuga, C. A. (2024). Unveiling novel serum biomarkers in intrahepatic cholangiocarcinoma: a pilot proteomic exploration. *Frontiers in Pharmacology*, 15, 1440985. ISSN: 1663-9812. FI: 5.988, Q1. PMID: 39286634.
24. Crăciun, R., Grapă, C., **Mocan T.**, Tefas, C., Nenu, I., Buliarcă, A., Ștefănescu, H., Nemeș, A., Procopetu, B., & Spârchez, Z. (2024). The Bleeding Edge: Managing Coagulation and Bleeding Risk in Patients with Cirrhosis Undergoing Interventional Procedures. *Diagnostics*, 14(22), 2602. ISSN: 2075-4418. FI: 3.600, Q2. PMID: 39594268.
25. Moldovan, S. A., Moiş, E. I., Graur, F., Puia, I. C., Vlad, I., Nechita, V. I., Furcea, L., Zaharie, F., Popa, C., Leucuța, D. C., Mirel, S., Moldovan, M. Ș., **Mocan T.**, Seicean, A., Ciocan, A., & Al Hajjar, N. (2025). A Systematic Review and Meta-Analysis of Preoperative Biliary Drainage Methods in Periapillary Tumors. *Journal of Clinical Medicine*, 14(19), 7097. ISSN: 2077-0383. FI: 3.900, Q1. PMID: 41096177.
26. Grapă, C., **Mocan T.**, Mocan, L. P., Motofealea, A., Stănculescu, R., Crăciun, R., Varcui, A., Spârchez, Z., & Mocan, T. (2025). Turning the Tide – Artificial Intelligence in the Evolving Landscape of Liver Cancer. *Cancers*, 17(18), 3003. ISSN: 2072-6694. FI: 6.575, Q1. PMID: 41008847.
27. Salzmann, R. J. S., & **Mocan T.**, et al. (2026). AI-guided additive scoring model for differential diagnosis of primary liver cancer. *JHEP Reports*, [de completat]. ISSN: 2589-5559. FI: 9.239, Q1. PMID: 41895662.

28. Słomka, A., Wang, B., **Mocan T.**, González-Carmona, M., Strassburg, C. P., Lukacs-Kornek, V., & Kornek, M. T. (2022). Extracellular vesicles small RNA clusters: hit the nail on the head of liver cancer detection. *Hepatobiliary Surgery and Nutrition*, 11(1), 100–102. ISSN: 2304-3881. FI: 6.007, Q1. PMID: 35284519.
29. Słomka, A., **Mocan T.**, Willms, A. G., Lukacs-Kornek, V., & Kornek, M. T. (2023). Hepatocellular carcinoma extracellular vesicle ECG score as a diagnostic tool close to the ideal. *Hepatobiliary Surgery and Nutrition*, 12(6), 930–932. ISSN: 2304-3881. FI: 6.007, Q1. PMID: 38115928.
30. van Keulen, A. M., Buettner, S., Olthof, P. B., et al. (including **Mocan T.**) (2024). Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease. *Annals of Surgical Oncology*, 31(10), 6495–6503. ISSN: 1068-9265. FI: 4.338, Q1. PMID: 38896226.
31. Crăciun, R., **Mocan T.**, Procopet, B., Nemeş, A., Tefas, C., Spârchez, M., Mocan, L. P., & Spârchez, Z. (2022). Pulmonary complications of portal hypertension: The overlooked decompensation. *World Journal of Clinical Cases*, 10(17), 5531–5540. ISSN: 2307-8960. FI: 1.557, Q3. PMID: 35979136.
32. Salzmann, R. J. S., Krötz, C., **Mocan T.**, Mocan, L. P., Grapă, C., et al. (2024). Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis. *Hepatology Communications*, 8(3), e0380. ISSN: 2471-254X. FI: 5.645, Q1. PMID: 38358371.
33. Słomka, A., Wang, B., **Mocan T.**, Horhat, A., Willms, A. G., et al. (2022). Extracellular Vesicles and Circulating Tumour Cells – complementary liquid biopsies or standalone concepts? *Theranostics*, 12(13), 5836–5855. ISSN: 1838-7640. FI: 11.600, Q1. PMID: 35966579.
34. Spârchez, Z., **Mocan T.**, Crăciun, R., Spârchez, M., & Nolsøe, C. (2022). Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect? *Ultrasonography*, 41(2), 263–278. ISSN: 2288-5919. FI: 3.491, Q2. PMID: 35073625.

35. Spârchez, Z., Radu, P., Bartoș, A., Nenu, I., Crăciun, R., **Mocan T.**, et al. (2021). Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? *World Journal of Gastrointestinal Oncology*, 13(12), 1896–1918. ISSN: 1948-5204. FI: 3.368, Q2. PMID: 35070032.
36. Słomka, A., **Mocan T.**, Wang, B., Nenu, I., Urban, S. K., et al. (2020). EVs as Potential New Therapeutic Tool/Target in Gastrointestinal Cancer and HCC. *Cancers*, 12(10), 3019. ISSN: 2072-6694. FI: 6.126, Q1. PMID: 33080904.
37. Popa, C., Schlanger, D., Buliarcă, A., **Mocan T.**, Procopet, B., Spârchez, Z., & Al Hajjar, N. (2021). Is There a Role for Surgery in BCLC B Hepatocellular Carcinoma? *Chirurgia (Bucharest)*, 116(eCollection), 1–8. ISSN: 1221-9118. FI: 0.800, Q4. PMID: 34463246.
38. Muñoz-Martínez, S., Sapena, V., Forner, A., Bruix, J., et al. (including **Mocan T.**) (2022). Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. *Liver International*, 42(8), 1891–1901. ISSN: 1478-3223. FI: 7.577, Q1. PMID: 35608939.
39. Muñoz-Martínez, S., Sapena, V., Forner, A., Nault, J. C., et al. (including **Mocan T.**) (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). *JHEP Reports*, 3(3), 100260. ISSN: 2589-5559. FI: 9.239, Q1. PMID: 33644725.
40. Matei, D., Crăciun, R., Crișan, D., Procopet, B., **Mocan T.**, et al. (2021). Hepatic Hydrothorax – An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. *Journal of Clinical Medicine*, 10(16), 3688. ISSN: 2077-0383. FI: 4.241, Q1. PMID: 34441984.
41. Nenu, I., Ștefănescu, H., Procopet, B., Spârchez, Z., Minciună, I., **Mocan T.**, et al. (2022). Navigating through the Lipid Metabolism Maze: Diagnosis and Prognosis Metabolites of Hepatocellular Carcinoma versus Compensated Cirrhosis. *Journal of Clinical Medicine*, 11(5), 1292. ISSN: 2077-0383. FI: 4.241, Q1. PMID: 35268381.
42. Urban, S. K., Sängler, H., Krawczyk, M., et al. (including **Mocan T.**) (2020). Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer

- differentiation. *Liver International*, 40(12), 3103–3116. ISSN: 1478-3223. FI: 7.577, Q1. PMID: 32614460.
43. Mocan, L. P., Rusu, I., Melincovici, C. S., Boşca, B. A., **Mocan T.**, et al. (2023). The Role of Immunohistochemistry in the Differential Diagnosis between Intrahepatic Cholangiocarcinoma, Hepatocellular Carcinoma and Liver Metastasis. *Diagnostics*, 13(9), 1542. ISSN: 2075-4418. FI: 3.600, Q2. PMID: 37174934.
 44. Crăciun, R., Buliarcă, A., Matei, D., Grapă, C., Nenu, I., Ștefănescu, H., **Mocan T.**, et al. (2024). Cirrhosis Progression Is Not Associated with Clinically Significant Alterations in Global Hemostasis Assessed by Thromboelastography. *Journal of Clinical Medicine*, 13(21), 6614. ISSN: 2077-0383. FI: 3.900, Q1. PMID: 39518754.
 45. Buliarcă, A., Horhat, A., **Mocan T.**, Crăciun, R., Procopeț, B., & Spârchez, Z. (2021). Viscoelastic tests in liver disease: where do we stand now? *World Journal of Gastroenterology*, 27(23), 3290–3302. ISSN: 1007-9327. FI: 5.374, Q1. PMID: 34163112.
 46. Banales, J. M., Rodrigues, P. M., Affò, S., et al. (International CCA Consortium, including **Mocan T.**) (2026). Cholangiocarcinoma 2026: status quo, unmet needs and priorities. *Nature Reviews Gastroenterology & Hepatology*, 23(1), 65–96. ISSN: 1759-5045. FI: 73.082, Q1. PMID: 41372578.
 47. Spârchez, Z., **Mocan T.**, Radu, P., Mocan, L. P., Spârchez, M., Leucuța, D. C., & Al Hajjar, N. (2018). Prognostic Factors after Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma. *Journal of Gastrointestinal and Liver Diseases*, 27(4), 399–407. ISSN: 1841-8724. FI: 1.880, Q3. PMID: 30574622.
 48. Moldovan S. A., **Mocan T** et al., (2025). Comparative Outcomes of Pancreaticogastrostomy and Pancreaticojejunostomy. *Medicina (Kaunas)*, ISSN: 1648-9144. FI: 2.430, Q2. PMID: 41303887.

ii. Articole în reviste indexate BDI

(Nu se aplică – toate articolele sunt publicate în reviste cotate ISI.)